We Claim:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein:

each of R^a and R^b is independently H or C_{1-3}alkyl;

R^1 is H, OH, C_{1-3}alkyl, OC_{1-3}alkyl, $=CH_2$, or $=NOR^5$; or R^1 is C_{3-6}cycloalkyl or C_{3-6}heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached;

each of R^{1a} and R^{1b} is independently H or C_{1-3} alkyl;

R^2 is C_{3-9}heterocycloalkyl or C_{3-9}heterocycloalkenyl, or R^2 is selected from the group consisting of  , and  , and R^6 is C_{1-6}alkyl, C_{3-8}cycloalkyl, or C_{6-10}aryl, or R^2 is selected from the group consisting of 





R^3 is C_{3-8}cycloalkyl, C_{3-8}cycloalkenyl, C_{3-7}heterocycloalkyl, or C_{2-6}heteroaryl;

R^4 is ~~C_{3-8}cycloalkyl, C_{3-9}heterocycloalkyl, C_{6-10}aryl,~~ or C_{2-6}heteroaryl, and R^4 is optionally substituted with one to three groups independently selected from halo, C_{1-3}alkyl, C_{1-3}alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each R^N is independently H or C_{1-3}alkyl;

each R^5 independently is H, C_{1-3}alkyl, or C_{0-2}alkylene-C_{6-10}aryl;

X is C_{1-3}alkylene;

Y is SO or SO_2; and

each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group independently has 1, 2, or 3 ring heteroatoms selected from N, O, and S.

2. The compound or salt of claim 1, wherein each Y is SO.

3. The compound or salt of claim 1, wherein each Y is SO_2.

4. The compound or salt of any one of claims 1-3, wherein R^a is H.

5. The compound or salt of any one of claims 1-3, wherein R^a is C_{1-3}alkyl.

6. The compound or salt of claim 5, wherein R^a is CH_3.

7. The compound or salt of any one of claims 1-6, wherein R^b is H.

8. The compound or salt of any one of claims 1-6, wherein R^b is C_{1-3}alkyl.

9. The compound or salt of claim 8, wherein R^a is CH_3.

10. The compound or salt of any one of claims 1-9, wherein R^1 is H, OH, or $=NOR^5$.

11. The compound or salt of claim 10, wherein R^5 is H or CH_3.

12. The compound or salt of any one of claims 1-9, wherein R^1 is C_{1-3}alkyl or OC_{1-3}alkyl.

13. The compound or salt of claim 12, wherein R^1 is CH_3 or OCH_3.

14. The compound or salt of claim 13, wherein R^1 is CH_3 and exhibits *S* stereochemistry.

15. The compound or salt of any one of claims 1-9, wherein R^1 is C_{3-6}cycloalkyl or C_{3-6}heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached.

16. The compound or salt of claim 15, wherein R^1 together with the ring atom to which it is attached forms  ,  , or  .

17. The compound or salt of any one of claims 1-9, wherein R^1 is $=CH_2$.

18. The compound or salt of any one of claims 1-17, wherein each of R^{1a} and R^{1b} is H.

19. The compound or salt of any one of claims 1-17, wherein at least one of of R^{1a} and R^{1b} is C_{1-3}alkyl.

20. The compound or salt of claim 19, wherein each of R^{1a} and R^{1b} is CH_3.

~~**21.** The compound or salt of any one of claims 1-20, wherein R^2 is C_{1-6}alkyl or $N(R^5)_2$.~~

~~**22.** The compound or salt of claim 21, wherein each R^5 independently comprises H, C_{1-3}alkyl, or benzyl.~~

~~**23.**~~**21.** The compound or salt of any one of claims 1-20, wherein R^2 comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, or tetrahydropyridinyl.

~~**24.** The compound or salt of any one of claims 1-20, wherein the C_{3-7}heterocycloalkyl or C_{3-7}heterocycloalkenyl of R^2 comprises a bridge or a spiro group.~~

~~**25.**~~**22.** The compound or salt of claim ~~24~~1, wherein ~~the C_{3-9}heterocycloalkyl comprising a bridge or a spiro group~~ R^2 is selected from the group consisting of

 ,  , and  , and R^6 is C_{1-6}alkyl, C_{3-8}cycloalkyl, or C_{6-10}aryl.

~~**26.**~~**23.** The compound or salt of claim ~~25~~22, wherein R^6 is phenyl optionally substituted with one to three groups independently selected from halo, C_{1-3}alkyl, C_{1-3}alkoxy, and CN.

~~**27.**~~**24.** The compound or salt of claim ~~23~~1, wherein R^2 is selected from the group consisting of

 ,  ,  ,  ,  ,

 ,  ,  ,  ,  ,  ,





~~28.~~25. The compound or salt of claim ~~27~~24, wherein R^2 is selected from the group consisting of  .

 ,  ,  ,

 , and  .

~~**29.** The compound or salt of any one of claims 1-28, wherein X is absent.~~

~~**30.**~~**26.** The compound or salt of any one of claims 1-~~28~~25, wherein X is CH_2, CH_2CH_2, or $CH(CH_3)$.

~~**31.**~~**27.** The compound or salt of any one of claims ~~30~~1-26, wherein R^3 comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl.

~~**32.**~~**28.** The compound or salt of claim ~~31~~26, wherein X-R^3 is selected from the group consisting of  ,

 ,

 ,

 , and .

~~**33.**~~**29.** The compound or salt of claim ~~32~~28, wherein X-R^3 is  ,  ,

 , or  .

~~34.~~30. The compound or salt of claim ~~33~~29, wherein X-R^3 is  , or  .

~~35.~~31. The compound or salt of any one of claims 1-~~34~~30, wherein R^4 comprises C_{3-8}cycloalkyl or C_{3-9}heterocycloalkyl.

~~36.~~32. The compound or salt of claim ~~35~~31, wherein R^4 is  or  .

~~37.~~33. The compound or salt of any one of claims 1-~~34~~32, wherein ~~R^4 comprises C_{6-10}aryl or C_{2-9}heteroaryl, and~~ R^4 is ~~optionally~~ substituted with one to three groups independently selected from halo, C_{1-3}alkyl, C_{1-3}alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each R^N is independently H or C_{1-3}alkyl.

~~38.~~34. The compound or salt of claim ~~37~~1, wherein R^4 is selected from the group consisting of  ,  ,  , and .

~~39.~~35. The compound or salt of claim ~~38~~34, wherein R^4 is  .

~~40.~~36. The compound or salt of claim 1, wherein:

R^a, R^b, R^{1a}, and R^{1b} are each H;

R^1 is $=CH_2$ or CH_3;

R^2 is  ;

X-R^3 is  ;

R^4 is  ; and

each Y is SO_2.

~~41.~~37. The compound or salt of any one of claims 1-~~40~~36, wherein R^1 is in a *(S)* configuration.

~~42.~~38. A compound listed in Table A, or a pharmaceutically acceptable salt thereof.

No.	Structure
A5	
A13	

A17	
A19	

A20	
A21	
A22	
A23	
A24	

A25	
A26	
A27	
A28	
A29	
A30	

A31	
A32	
A33	
A34	
A35	
A36	

A37	
A38	
A39	
A40	
A41	
A42	

A43	
A44	
A46	
A47	
A48	
A49	

A50	
A51	
A52	
A53	
A54	
A55	

A56	
A57	
A58	
A59	
A60	
A61	

A63	
A64	
A65	
A66	
A67	
A68	

A69	
A70	
A71	
A72	
A73	
A74	

A75	
A76	
A77	
A78	
A79	
A80	

A81	
A82	
A83	
A84	
A85	
A86	

A87	
A88	
A89	
A90	
A91	

A92	
A93	
A94	
A95	
A96	

A97	
A98	
A99	
A100	
A101	

A102	
A104	
A108	
A109	
A110	

A111	
A112	
A113	
A114	

A115	
A116	
A117	
A118	

A119	
A120	
A121	
A122	
A123	
A124	

A125	
A126	
A127	
A128	
A129	
A130	

A134	
A135	
A136	
A137	
A138	
A142	

A143	
A144	
A145	
A146	
A147	
A148	

A149	
A150	
A151	
A153	
A154	

A155	
A157	
A160	
A161	
A162	

A163	
A164	
A166	
A168	
A169	
A170	

A171	
A172	
A173	
A174	
A175	

A176	
A177	
A178	
A179	
A180	
A181	

A182	
A183	
A185	
A188	
A190	
A191	

A193	
A194	
A195	
A196	
A197	

A198	
A199	
A200	
A201	
A202	

A203	
A204	
A206	
A207	
A208	

A209	
A210	

~~43.~~39. The compound or salt of claim ~~42~~38, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,


,

,

, and

.

~~44.~~40. A pharmaceutical composition comprising the compound or salt of any one of claims 1-~~43~~39 and a pharmaceutically acceptable carrier.

~~45.~~41. The compound or salt of any one of claims 1-~~43~~39, or the pharmaceutical composition of claim ~~44~~40, for use as a treatment of cancer.

~~46.~~42. The compound or salt of any one of claims 1-~~43~~39, or the pharmaceutical composition of claim ~~44~~40, for use as a medicament.

~~47.~~43. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for treating inflammation in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~48.~~44. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for treating or preventing cancer or a precancerous condition in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~49.~~45. The use of claim ~~48~~44, wherein the cancer is melanoma, multiple myeloma, prostate cancer, lung cancer, pancreatic cancer, squamous cell carcinoma, leukemia, lymphoma, a neuroendocrine tumor, bladder cancer, or colorectal cancer.

~~50.~~46. The use of claim ~~48~~44, wherein the cancer is non small cell lung carcinoma, squamous cell carcinoma, leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, lymphoma, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, neuroendocrine tumors, breast cancer, mantle cell lymphoma, renal cell carcinoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, small cell carcinoma, adenocarcinoma, gastric carcinoma, hepatocellular carcinoma, pancreatic cancer, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, or head and neck cancer.

~~51.~~47. The use of claim ~~48~~44, wherein the cancer is a solid tumor.

~~52.~~48. The use of claim ~~48~~44, wherein the cancer is head and neck cancer, squamous cell carcinoma, gastric carcinoma, or pancreatic cancer.

~~53.~~49. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for treating an autoimmune disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~54.~~50. The use of claim ~~53~~49, wherein the autoimmune disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn's disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid

bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

~~55.~~51. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for the treatment of an immune-related disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~56.~~52. The use of claim ~~55~~51, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease.

~~57.~~53. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for treating neurodegenerative disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~58.~~54. The use of claim ~~57~~53, wherein the neurodegenerative disease is multiple sclerosis.

~~59.~~55. Use of the compound or salt of any one of claims 1-~~43~~39 or the pharmaceutical composition of claim ~~44~~40, in the manufacture of a medicament for treating an inflammatory disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

~~60.~~56. The use of claim ~~59~~55, wherein the inflammatory disease is bronchitis, conjunctivitis, myocarditis, pancreatitis, chronic cholecstitis, bronchiectasis, aortic valve stenosis, restenosis, psoriasis or arthritis.